Journal
NEURO-ONCOLOGY
Volume 16, Issue -, Pages viii7-viii13Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nou232
Keywords
EGFRvIII; epidermal growth factor receptor; glioblastoma; tyrosine kinase inhibitor
Categories
Funding
- NINDS NIH HHS [R01 NS080944] Funding Source: Medline
Ask authors/readers for more resources
Epidermal growth factor receptor (EGFR) has emerged as a highly attractive therapeutic target in glioblastoma (GBM) based on its high frequency of gene amplification and mutation and its identification as an upstream trigger of dysregulated cell signaling cascades that drive GBM pathophysiology. Extensive investment has been committed in an attempt to exploit EGFR therapeutically to improve outcome for GBM patients, including the development of a variety of EGFR-targeting therapeutics as well as the participation of hundreds of participants in multiple, carefully constructed clinical trials. In this review, we summarize the design and results of clinical trials evaluating EGFR tyrosine kinase inhibitors in recurrent and newly diagnosed GBM patients. While overall results thus far have been disappointing, it is premature to discount EGFR as a therapeutic target in GBM on the basis of these studies given the limitations in study design and the pharmacology of first-generation EGFR kinase inhibitors. Although important lessons have been learned, critical questions remain unanswered and warrant further study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available